The native SARS-CoV-2 spike glycoprotein (S) mediates the entry of the virus into target cells via its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor, thereby initiating the infection. It forms a homotrimeric structure on the surface of the SARS-CoV-2 virus and represents the major target for diagnostic and therapeutic agents. The ectodomain of the S glycoprotein comprises the N-terminal S1 subunit, including the receptor binding domain, and the C-terminal S2 subunit.
The recombinant SARS-CoV-2 Spike-S1 (HEK) covers the S1 domain of the viral surface protein including amino

Data and images for Recombinant SARS-CoV-2 Spike-S1 (HEK)

Figures

Figure 1

View details
Bead-based immunoassay for detection of patient-derived SARS-CoV-2 antibodies
. Schematic overview illustrating how our biotinylated antigens can be applied to detect patient-derived SARS-CoV-2 antibodies

Figure 1

Bead-based immunoassay for detection of patient-derived SARS-CoV-2 antibodies
. Schematic overview illustrating how our biotinylated antigens can be applied to detect patient-derived SARS-CoV-2 antibodies

Figure 2

View details
Results of the bead-based immunoassay using biotinylated Recombinant SARS-CoV-2 Spike-S1 (HEK).
The amount of captured SARS-CoV-2 antibodies was quantified at different plasma dilutions. Results for plasma from a COVID-19+ patient (circle) or a healthy donor (square) are shown.

Figure 2

Results of the bead-based immunoassay using biotinylated Recombinant SARS-CoV-2 Spike-S1 (HEK).
The amount of captured SARS-CoV-2 antibodies was quantified at different plasma dilutions. Results for plasma from a COVID-19+ patient (circle) or a healthy donor (square) are shown.

Figure 3

View details
SDS-PAGE of biotinylated Recombinant SARS-CoV-2 Spike S1 (HEK)
under reduced (R) and non-reduced (NR) conditions.

Figure 3

SDS-PAGE of biotinylated Recombinant SARS-CoV-2 Spike S1 (HEK)
under reduced (R) and non-reduced (NR) conditions.

Specifications for Recombinant SARS-CoV-2 Spike-S1 (HEK)

Overview

The native SARS-CoV-2 spike glycoprotein (S) mediates the entry of the virus into target cells via its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor, thereby initiating the infection. It forms a homotrimeric structure on the surface of the SARS-CoV-2 virus and represents the major target for diagnostic and therapeutic agents. The ectodomain of the S glycoprotein comprises the N-terminal S1 subunit, including the receptor binding domain, and the C-terminal S2 subunit.
The recombinant SARS-CoV-2 Spike-S1 (HEK) covers the S1 domain of the viral surface protein including amino acids V16 to P681 of the native S glycoprotein. The protein is extended at its C-terminus with a His-tag and an AviTag. The recombinant SARS-CoV-2 Spike-S1 (HEK)-Biotin is specifically biotinylated at a single site, preserving full functionality of the protein.

Related products for
Recombinant SARS-CoV-2 Spike-S1 (HEK)

7 products available | view all

Seems like you are coming from USA!
Do you want to visit our website in your country?